{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:56Z","timestamp":1789391696709,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the increasing use of Janus kinase (JAK) inhibitors in immune-related conditions, their potential role in AA treatment is gaining attention. Deuruxolitinib has emerged as a potential treatment for moderate to severe AA. This is the first systematic review and meta-analysis that aims to assess the efficacy of deuruxolitinib in moderate to severe AA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched Cochrane Central Register of Controlled Trials (CENTRAL), Medline, and <jats:uri>ClinicalTrials.gov<\/jats:uri> for relevant data. Deuruxolitinib vs. placebo was evaluated, and efficacy was measured using severity of alopecia tool (SALT) and Hair Satisfaction Participants Reported Outcome (SPRO), with the primary time point of assessment at week 24. Treatment-emergent adverse events (TEAEs) such as increased creatinine kinase (CPK), acne, and headache were specifically assessed at week 28. Effect sizes were presented using mean difference (MD) or risk ratio (RR). Statistical heterogeneity was measured by <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>, with a 95% confidence interval (CI) and <jats:italic>p<\/jats:italic>-value less than 0.05 considered significant. Risk of bias was assessed using the Revised Cochrane risk of bias tool. Subgroup analysis was conducted for different regimens (8\u202fmg and 12\u202fmg) and TEAEs of interest. This research was registered in PROSPERO (CRD42023417104).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three randomized controlled trials involving 1,372 patients were included. Deuruxolitinib demonstrated a significant improvement in SALT score change from baseline [MD\u202f=\u202f\u221247.26, 95% CI\u202f=\u202f(\u221253.47, \u221241.05), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f76%], with a significant number of patients achieving 75% [RR\u202f=\u202f93.66, 95% CI\u202f=\u202f(23.42, 374.65), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f0%] and 90% [RR\u202f=\u202f65.26, 95% CI\u202f=\u202f(16.28, 261.58), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f0%] improvement from baseline. Patients randomized to deuruxolitinib reported a significant improvement in SPRO [MD\u202f=\u202f\u22121.52, 95% CI\u202f=\u202f(\u22121.76, \u22121.27), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f69%], with many experiencing more than two points of improvement [RR\u202f=\u202f4.98, 95% CI\u202f=\u202f(3.79, 6.54), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.00001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f0%]. TEAEs included elevated CPK levels [RR\u202f=\u202f2.79, 95% CI\u202f=\u202f(1.5, 4.99), <jats:italic>p<\/jats:italic>\u202f=\u202f0.0006, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f0%], headaches [RR\u202f=\u202f1.49, 95% CI\u202f=\u202f(0.98, 6.54), <jats:italic>p<\/jats:italic>\u202f=\u202f0.06, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f44%], and acne (significant in the 12\u202fmg dose only) [RR\u202f=\u202f1.80, 95% CI\u202f=\u202f(0.84, 3.88), <jats:italic>p<\/jats:italic>\u202f=\u202f0.13, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> =\u202f64%].<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In conclusion, deuruxolitinib shows promising efficacy in treating moderate to severe AA, leading to significant improvements in hair regrowth and patient-reported satisfaction. While certain TEAEs such as increased CPK levels, headaches, and acne (especially at the 12\u202fmg dose), they were generally manageable. Further research and vigilant monitoring for long term safety are necessary before widespread adoption of deuruxolitinib for AA treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1641245","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:26:53Z","timestamp":1759850813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Mulham","family":"Kalantan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Bashrahil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Aljuaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Bogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahal","family":"Samarkandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhadi","family":"Jfri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-4632.2007.03193.x","article-title":"Alopecia areata","volume":"46","author":"Wasserman","year":"2007","journal-title":"Int J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaad.2017.06.035","article-title":"Prevalence of pediatric alopecia areata among 572, 617 dermatology patients","volume":"77","author":"Caldwell","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1468-3083.1997.tb00225.x","article-title":"The genetic epidemiology and autoimmune pathogenesis of alopecia areata","volume":"9","author":"McMichael","year":"1997","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"adv 00855","DOI":"10.2340\/actadv.v103.4536","article-title":"Comparative efficacy and safety of Janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis","volume":"103","author":"Sedeh","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"ref9","article-title":"Alopecia areata","volume-title":"Stat pearls","author":"Lepe","year":"2024"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1152513","DOI":"10.3389\/fimmu.2023.1152513","article-title":"Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e142205","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The alopecia areata consensus of experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref16","year":"2023"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.25259\/IJDVL_975_19","article-title":"Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis","volume":"87","author":"Yu","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1195858","DOI":"10.3389\/fimmu.2023.1195858","article-title":"The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients","volume":"14","author":"Mao","year":"2023","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"104157","DOI":"10.1016\/j.amsu.2022.104157","article-title":"Olumniant (Baricitinib) oral tablets: an insight into FDA-approved systemic treatment for alopecia areata","volume":"80","author":"Ali","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2320351","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus kinase inhibitors for alopecia areata","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/jidsymp.2013.14","article-title":"Current treatment of alopecia areata","volume":"16","author":"Shapiro","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/archderm.1979.04010100058026","article-title":"Treatment of alopecia areata by anthralin-induced dermatitis","volume":"115","author":"Schmoeckel","year":"1979","journal-title":"Arch Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0733-8635(18)30280-8","article-title":"Alopecia areata. Update on therapy","volume":"11","author":"Shapiro","year":"1993","journal-title":"Dermatol Clin"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1641245\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:26:54Z","timestamp":1759850814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1641245\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1641245"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1641245","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1641245"}}